Goldman Sachs
SLS icon

Goldman Sachs’s SELLAS Life Sciences SLS Stock Holding History

Goldman Sachs’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-59
Closed -$23K – 6353
2017
Q4 		$23K Hold
59
– – ﹤0.01% 6096
2017
Q3 		$31K Hold
59
– – ﹤0.01% 6359
2017
Q2 		$52K Hold
59
– – ﹤0.01% 6353
2017
Q1 		$54K Sell
59
-32
-35% -$53K ﹤0.01% 6265
2016
Q4 		$264K Buy
+91
New +$529K ﹤0.01% 5577

Other funds holding SLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Goldman Sachs's SLS Position: Q1 2026 in Review

Goldman Sachs increased its SELLAS Life Sciences (SLS) stake by 35% in Q1 2026, buying an estimated $645K and bringing the position to 555,913 shares worth $2.35M. The position accounts for ﹤0.01% of the portfolio, ranked #4395.

Goldman Sachs first reported a position in SLS in Q4 2016 and has held it in 10 quarters since. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

  • Goldman Sachs held 555,913 shares of SELLAS Life Sciences worth $2.35M as of Q1 2026.
  • Goldman Sachs bought 144,259 SELLAS Life Sciences shares in Q1 2026, an estimated $645K.
  • SELLAS Life Sciences made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4395 holding.
  • Goldman Sachs first reported a position in SELLAS Life Sciences in Q4 2016 and has held it in 10 quarters since.
  • 160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.